Niraparib Clinical Trials (2026): 199 Studies for Ovarian Cancer & Ovarian Neoplasms

Where to Participate: All Niraparib Trial Sites in the U.S. (94 sites across 30 states)

Every actively recruiting Niraparibtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

Niraparib clinical trials at a glance: phase × recruitment status

Recruiting Niraparib clinical trials (39)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

Niraparib clinical trials by indication

Niraparib pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

Terminated and withdrawn Niraparib trials (38)

Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.

• NCT06161493withdrawnZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors
• NCT06392841withdrawnNiraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations
• NCT06329830withdrawn177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer
• NCT06527690withdrawnRace Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate Cancer
• NCT06365970withdrawnNiraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers
• NCT04149145withdrawnTrial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer
• NCT05672095withdrawnNiraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer
• NCT05126342withdrawnStudy to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi
• NCT05238831withdrawnSMMART Adaptive Clinical Treatment (ACT) Trial
• NCT05289648withdrawnNiraparib in High-grade Endometrial Cancer Trial
• NCT04762901withdrawnLCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer
• NCT05174455withdrawnNiraparib for the Treatment of Leiomyosarcoma
• NCT04030559terminatedNiraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects
• NCT04159155terminatedA Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer
• NCT04544995terminatedDose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)
• NCT04861181terminatedNIRAPK : Study of the Relationship(s) Between Clinical, Biological and Pharmacokinetic Metrics and Toxicities When Niraparib is Used as Maintenance Treatment for Ovarian Cancer Patients.
• NCT06964165terminatedA Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)
• NCT04779151terminatedBasket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab
• NCT05523440terminatedBevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation
• NCT03806049withdrawnTrial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer
• NCT04926324terminatedA Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers
• NCT03891576terminatedNewton Study (NEW Dosing MainTenance Therapy Ovarian CaNcer)
• NCT05442749terminatedNiraparib as First Line Therapy With Metastatic Homologous Repair-deficient Pancreatic Cancer
• NCT05169437terminatedNiraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
• NCT04826198terminatedSafety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months
• NCT05297864terminatedPARP Inhibition for Gliomas (PI-4G or π4g)
• NCT04267939terminatedATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer
• NCT03209401terminatedNiraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies
• NCT05666349withdrawnReirradiation and Niraparib in Patients With Recurrent Glioblastoma
• NCT04895046withdrawnMaintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma
• NCT05412706withdrawnNiraparib Maintenance Treatment in mCRC With a Partial o Complete Response After Oxaliplatin-based Induction Therapy
• NCT04655183withdrawnStudy of M4344 in Combination With Niraparib
• NCT03840967terminatedA Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma
• NCT02826512terminatedA Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer Patients
• NCT04178460terminatedA Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment
• NCT03955471terminatedStudy to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer
• NCT01905592terminatedA Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
• NCT02500901terminatedEnzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)

All Niraparib trials (199)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

Niraparib clinical trials: frequently asked questions

How many Niraparib clinical trials are there?

199 Niraparib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 33 are actively recruiting participants. 56 are marked completed.

Are Niraparib clinical trials recruiting in 2026?

Yes — 33 Niraparib trials are actively recruiting in 2026, with 94 U.S. sites across 30 states. See the recruiting trials and the per-state site list further down this page.

What conditions is Niraparib being studied for?

Niraparib is being studied for Ovarian Cancer, Ovarian Neoplasms, Breast Cancer, Fallopian Tube Cancer, Neoplasms and 345 more. The trials are grouped by indication on this page.

What phase is Niraparib in?

Niraparib clinical trials span 5 Phase 4, 18 Phase 3, 100 Phase 2, 35 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors Niraparib clinical trials?

The lead sponsor across the most Niraparib trials is Tesaro, Inc., with 130 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Niraparibas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed June 12, 2026.